Cardiac Department, A.O. Fatebenefratelli, Milano, Italy.
Cardiac Department, A.O. Fatebenefratelli, Milano, Italy.
JACC Cardiovasc Interv. 2015 Dec 28;8(15):2003-2009. doi: 10.1016/j.jcin.2015.08.029. Epub 2015 Nov 25.
The authors sought to understand the clinical and angiographic outcomes of dissections left after drug-coated balloon (DCB) angioplasty.
Second-generation DCB may be an alternative to stents in selected populations for the treatment of native coronary lesions. However, the use of these devices may be hampered by a certain risk of acute vessel recoil or residual coronary dissection. Moreover, stenting after DCB has shown limited efficacy. Little is known about when a non-flow-limiting dissection is left after DCB angioplasty.
This was a prospective observational study whose aim was to investigate the outcome of a consecutive series of patients with native coronary artery disease treated with second-generation DCB and residual coronary dissection at 2 Italian centers. We evaluated patient clinical conditions at 1 and 9 months, and angiographic follow up was undertaken at 6 months.
Between July 2012 and July 2014, 156 patients were treated with DCB for native coronary artery disease. Fifty-two patients had a final dissection, 4 of which underwent prosthesis implantation and 48 were left untreated and underwent angiographic follow-up after 201 days (interquartile range: 161 to 250 days). The dissections were all type A to C, and none determined an impaired distal flow. Complete vessel healing at angiography was observed in 45 patients (93.8%), whereas 3 patients had persistent but uncomplicated dissections, and 3 had binary restenosis (6.2%). Late lumen loss was 0.14 mm (-0.14 to 0.42). Major adverse cardiovascular events occurred in 11 patients in the entire cohort and in 4 of the dissection cohort (7.2% vs. 8.1%; p = 0.48). We observed 8 and 3 target lesion revascularizations, respectively (5.3% vs. 6.2%; p = 0.37).
In this cohort of consecutive patients treated with new-generation DCB and left with a final dissection, this strategy of revascularization seemed associated with the sealing of most of dissections and without significant neointimal hyperplasia.
作者旨在了解药物涂层球囊(DCB)血管成形术后遗留夹层的临床和血管造影结果。
第二代 DCB 可能是治疗原发性冠状动脉病变的一种替代支架的选择,用于某些人群。然而,这些设备的使用可能会受到急性血管回缩或残留冠状动脉夹层的一定风险的阻碍。此外,DCB 后支架置入的效果有限。对于 DCB 血管成形术后遗留非血流受限的夹层知之甚少。
这是一项前瞻性观察性研究,旨在调查意大利的 2 个中心连续系列接受第二代 DCB 治疗的原发性冠状动脉疾病患者的结局,这些患者在 DCB 血管成形术后遗留冠状动脉夹层。我们评估了患者在 1 个月和 9 个月时的临床情况,并在 6 个月时进行了血管造影随访。
2012 年 7 月至 2014 年 7 月,156 例原发性冠状动脉疾病患者接受了 DCB 治疗。52 例患者有最终夹层,其中 4 例接受了假体植入,48 例未接受治疗,并在 201 天后(四分位距:161-250 天)进行了血管造影随访。夹层均为 A 至 C 型,均无远端血流受损。45 例患者(93.8%)在血管造影时完全愈合,而 3 例患者有持续但无并发症的夹层,3 例患者有双支再狭窄(6.2%)。晚期管腔丢失为 0.14mm(-0.14 至 0.42)。整个队列中有 11 例患者发生了主要不良心血管事件,在夹层队列中有 4 例(7.2%比 8.1%;p=0.48)。分别发生 8 例和 3 例靶病变血运重建(5.3%比 6.2%;p=0.37)。
在这组接受新一代 DCB 治疗并遗留最终夹层的连续患者中,这种血管重建策略似乎与大多数夹层的封闭相关,并且没有明显的新生内膜增生。